Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBETTM BET inhibitor platform on May 17th   BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the quarter ended March 31, 2022 and provided a business update. “VYNE made significant progress in the first quarter of 2022 with our pipeline of novel programs…